Patients With High Levels of Circulating Endothelial Progenitor Cells (EPC) Following at Least Three Months of Anticoagulation for Unprovoked Venous Thromboembolism (VTE) Are at Low Risk of Recurrent VTE—Results From the ExACT Randomised Controlled Trial.
EClinicalMedicine - United Kingdom
doi 10.1016/j.eclinm.2019.11.011
Full Text
Open PDFAbstract
Available in full text
Categories
Date
December 1, 2019
Authors
Publisher
Elsevier BV